NASDAQ: CVCapsovision Inc Stock
$7.28-0.09 (-1.22%)
Updated Jul 2, 2026
CV Price
$7.28
Fair Value Price
-$2.25
Market Cap
$363.73M
52 Week Low
$3.45
52 Week High
$15.37
P/E
-3.14x
P/B
17.99x
P/S
25.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.56M
Earnings
-$26.97M
Gross Margin
51.7%
Operating Margin
-198.69%
Profit Margin
-198.9%
Debt to Equity
0.28
Operating Cash Flow
-$24M
Beta
1.02
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CV Overview
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CV's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
CV
Ranked#52 of 93
Ranked#52 of 93
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.48 | A | |
| $45.43 | A | |
| $31.35 | A |
Be the first to know about important CV news, forecast changes, insider trades & much more!
CV News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CV ($7.28) is overvalued by 424.07% relative to our estimate of its Fair Value price of -$2.25 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CV ($7.28) is not significantly undervalued (424.07%) relative to our estimate of its Fair Value price of -$2.25 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CV due diligence checks available for Premium users.
Valuation
CV fair value
Fair Value of CV stock based on Discounted Cash Flow (DCF)
Price
$7.28
Fair Value
-$2.25
Undervalued by
424.07%
CV ($7.28) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CV ($7.28) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.14x
Industry
20.9x
Market
8.54x
CV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
17.99x
Industry
3.11x
CV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CV's financial health
Profit margin
Revenue
$2.8M
Net Income
-$7.0M
Profit Margin
-251.9%
CV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$25.9M
Liabilities
$5.7M
Debt to equity
0.28
CV's short-term assets ($24.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CV's short-term assets ($24.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.1M
Investing
-$48.0k
Financing
$14.0M
CV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CV vs Medical Device Stocks
Capsovision Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.